One of the most renowned and fancied counter among the Health Care division.Its growth in USA has been good. It grew by 222% in the quarter backed by a 123% growth in the base US operations and the balance from Morton Grove. More than 60 products are now marketed in US. In European markets, UK leads the way with a 20% growth.
The management have serious concerns for research & development.During the quarter, the company spent Rs.13.90 crore on R&D, which was an increase on 19% on a YoY. The company for now, has postponed the demerger of R&D division into a separate unit.
The Company has posted results for the period ended 30th September 2008.Net revenue rose on a YoY for Q3 by 25% to Rs. 923.50 crore. Business in India grew 11% while international by 31%. Formulations grew by 26% while bulk by 11%. EBIDTA was up 17% at Rs.210.80 crore. OPM was at 22.8%. But the good story ends here. PAT was down 43% at Rs.62.20 crore. This was mainly on account of a MTM forex loss of Rs.55.30 crore. Interest outgo was also very high at Rs.48.59 crore as against Rs.26.80 crore in last Q3.
The stock touched a new low at Rs.100 and even now, it remains subdued at Rs.108.The stock doesn't seems to be attractive for a good investment opportunity.
Disclaimer : I do not have any personal holding in this stock.